WO2001070686A1 - 5-hydroxy indole derivatives for treating glaucoma - Google Patents
5-hydroxy indole derivatives for treating glaucoma Download PDFInfo
- Publication number
- WO2001070686A1 WO2001070686A1 PCT/US2000/031144 US0031144W WO0170686A1 WO 2001070686 A1 WO2001070686 A1 WO 2001070686A1 US 0031144 W US0031144 W US 0031144W WO 0170686 A1 WO0170686 A1 WO 0170686A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indol
- ester
- compounds
- compound
- aminopropyl
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract description 13
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical class OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- GIJDPCHGGMSPEW-UHFFFAOYSA-N [3-(2-aminopropyl)-1h-indol-5-yl] 2-methylpropanoate Chemical compound C1=C(OC(=O)C(C)C)C=C2C(CC(N)C)=CNC2=C1 GIJDPCHGGMSPEW-UHFFFAOYSA-N 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- QXNAUBGLKTYBMO-UHFFFAOYSA-N [3-(2-aminopropyl)-1h-indol-5-yl] 2,2-dimethylpropanoate Chemical compound C1=C(OC(=O)C(C)(C)C)C=C2C(CC(N)C)=CNC2=C1 QXNAUBGLKTYBMO-UHFFFAOYSA-N 0.000 claims 2
- KRNLEDZEODKMNQ-UHFFFAOYSA-N [3-(2-aminopropyl)-1h-indol-5-yl] cyclopropanecarboxylate Chemical compound C1=C2C(CC(N)C)=CNC2=CC=C1OC(=O)C1CC1 KRNLEDZEODKMNQ-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004410 intraocular pressure Effects 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030043 Ocular hypertension Diseases 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- LYPCGXKCQDYTFV-UHFFFAOYSA-N alpha-methylserotonin Chemical class C1=C(O)C=C2C(CC(N)C)=CNC2=C1 LYPCGXKCQDYTFV-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 hydroxytryptamine compound Chemical class 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000004382 visual function Effects 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GGUSQTSTQSHJAH-FQEVSTJZSA-N (R)-eliprodil Chemical compound C([C@H](O)C=1C=CC(Cl)=CC=1)N(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-FQEVSTJZSA-N 0.000 description 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BXEFQUSYBZYTAE-UHFFFAOYSA-N 2-indol-1-ylethanamine Chemical class C1=CC=C2N(CCN)C=CC2=C1 BXEFQUSYBZYTAE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 238000005679 Batcho-Leimgruber synthesis reaction Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 0 CC(CC(C1=C2)=CN(*)C1=CC(C)(*)C=C2OC(*)=O)N Chemical compound CC(CC(C1=C2)=CN(*)C1=CC(C)(*)C=C2OC(*)=O)N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 238000010715 Leimgruber–Batcho indole synthesis reaction Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical class C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- AWCLNFQLEZLLHA-UHFFFAOYSA-N [3-(2-aminopropyl)-1h-indol-5-yl] propanoate Chemical compound CCC(=O)OC1=CC=C2NC=C(CC(C)N)C2=C1 AWCLNFQLEZLLHA-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- QSQQQURBVYWZKJ-UHFFFAOYSA-N alpha-methyltryptamine Chemical class C1=CC=C2C(CC(N)C)=CNC2=C1 QSQQQURBVYWZKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940095437 iopidine Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229960004771 levobetaxolol Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 230000004493 normal intraocular pressure Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003151 propanoic acid esters Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Definitions
- the present invention is directed to novel substituted 3-(2-aminopropyl)-lH- indol-5-ols. These novel compounds are useful for lowering and controlling normal or elevated intraocular pressure (IOP) and treating glaucoma.
- IOP intraocular pressure
- glaucoma The disease state referred to as glaucoma is characterized by a permanent loss of visual function due to irreversible damage to the optic nerve.
- the several morphologically or functionally distinct types of glaucoma are typically characterized by elevated IOP, which is considered to be causally related to the pathological course of the disease.
- Ocular hypertension is a condition wherein intraocular pressure is elevated but no apparent loss of visual function has occurred; such patients are considered to be a high risk for the eventual development of the visual loss associated with glaucoma. If glaucoma or ocular hypertension is detected early and treated promptly with medications that effectively reduce elevated intraocular pressure, loss of visual function or its progressive deterioration can generally be ameliorated.
- Drug therapies that have proven to be effective for the reduction of intraocular pressure include both agents that decrease aqueous humor production and agents that increase the outflow facility. Such therapies are in general administered by one of two possible routes, topically (direct application to the eye) or orally.
- U.S. Patent 5,874,477 discloses a method for treating malaria using 5-HT 2A/2C agonists.
- U.S. Patent 5,902,815 discloses the use of 5-HT 2A agonists to prevent adverse effects of NMDA receptor hypo-function.
- WO98/31354A2 discloses 5-HT B agonists for the treatment of depression and other CNS conditions.
- O00/12475 discloses indoline derivatives as 5-HT 2B and 5-HT 2C receptor agonists for the treatment of a variety of disorders of the central nervous system, but especially for the treatment of obesity.
- WO00/35922 discloses certain pyrazino[l ,2- ⁇ ]quinoxaline derivates as 5-HT 2 c agonists for the treatment of obsessive-compulsive disorder, depression, eating disorders, and other disorders involving the CNS.
- Agonist response at the 5-HT A receptor is reported to be the primary activity responsible for hallucinogenic activity, with some lesser involvement of the 5-HT 2 receptor possible [Psychopharmacology, Vol. 121 :357, 1995].
- the present invention is directed to new derivatives of 3-(2-aminopropyl)-lH- indol-5-ol which can be used to lower and control IOP associated with normal-tension glaucoma, ocular hypertension, and glaucoma in warm blooded animals, including man.
- the compounds are formulated in pharmaceutical compositions suitable for topical delivery to the eye.
- G is chosen from hydrogen, halogen, or C ⁇ aHcyl
- R is chosen from C 3 . 6 alkyl, C 3 . 6 alkyl substituted with hydroxyl, CO(OC ] - alkyl),
- R 1 is chosen from hydrogen, C ⁇ aHcyl; and pharmaceutically acceptable salts and solvates of the compounds.
- the total number of carbon atoms in a substituent group is indicated by the Ci-j prefix where the numbers i and j define the number of carbon atoms; this definition includes branched chain, and cyclic alkyl or (cyclic alkyl)alkyl groups. It is important to recognize that a substituent may be present either singly or multiply when incorporated into the indicated structural unit.
- the substituent halogen which means fluorine, chlorine, bromine, or iodine, would indicate that the unit to which it is attached may be substituted with one or more halogen atoms, which may be the same or different.
- the compounds of Formula I can be readily prepared from, for example, ⁇ - methyl-5-hydroxy-tryptarnine [J. Med. Chem. 33, 755 (1990), J. Org. Chem. 25, 1548 (I960)] or a desirably substituted derivative of structure 1 wherein G is as defined previously. That is, compounds of Formula I can be prepared by reacting the appropriate indole 1, or preferably a suitable amino-protected intermediate, e.g. 2 (Scheme 1 ) with the desired activated acid derivative, such as an acid halide or active ester, or the like, to provide the esters 3. Removal of the N-protective group from the intermediate 3 provides the desired compounds of Formula I.
- the indole derivatives of interest for use as starting materials for the preparation of 1 can be either purchased from commercial suppliers or prepared by well known methods [Comp. Heterocycl. Chem. II, Vol. 2: 1 19, 1996; Indoles, Sundberg, 1996].
- one such approach begins with the desired 5-alkoxy- 2-nitrotoluene 5 and proceeds via a Leimgruber-Batcho indole synthesis [J. Med.Chem. 22, 63 (1979) and U.S. Patent 3,732,245] to give the desired indoles 7 (Scheme 2).
- Intermediates 7 can be readily transformed into indoles 1 by well known methods [J. Med. Chem. 33, 755 (1990), J. Org. Chem. 25, 1548 (I960)].
- the compounds of this invention can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g.. topically, intracamerally, or via an implant).
- the compounds are preferably incorporated into topical ophthalmic formulations for delivery to the eye.
- the compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution.
- Ophthalmic solution formulations may be prepared by dissolving a compound in a physiologically acceptable isotonic aqueous buffer.
- the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound.
- the ophthalmic solution may contain an agent to increase viscosity, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac.
- Gelling agents can also be used, including, but not limited to, gellan and xanthan gum.
- the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum.
- Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-974. or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
- the compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 5 to 8.
- the compounds will normally be contained in these formulations in an amount 0.01% to 5% by weight, but preferably in an amount of 0.25% to 2% by weight.
- 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.
- the compounds can also be used in combination with other agents for treating glaucoma, such as, but not limited to, ⁇ -blockers (e.g., timolol. betaxolol, levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), ⁇ l antagonists (e.g.
- nipradolol nipradolol
- ct2 agonists e.g., iopidine and brimonidine
- miotics e.g., pilocarpine and epinephrine
- prostaglandin analogs e.g., latanoprost, travaprost, unoprostone, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368; and 5,151,444, "hypotensive lipids" (e.g., lumigan and compounds set forth in 5,352,708)
- neuroprotectants e.g., compounds from U.S. Patent No. 4,690,931, particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N. 06/203350, and appropriate compounds from WO94/13275, including memantine.
- Step A [2-(5-Hydroxy-lJ7-indol-3-yI)-l-methylethyl]carbamic acid 9//-fluoren-9- ylmethyl ester
- Step A Isobutyric acid 3-[2-(9-fl r -fluoren-9-ylmethoxycarbonylamino)-propyl]- li/-indol-5-yl ester
- Step A 2,2-Dimethyl-propionic acid 3-[2-(9 /-fluoren-9- ylmethoxycarbonylamino)-propyl]-l//-indol-5-yl ester
- Step B 2,2-Dimethyl-propionic acid 3-(2-aminopropyl)-l-ff-indol-5-yl ester
- Step A Cyclopropanecarboxylic acid 3-[2-(9 jT-fluoren-9- ylmethoxycarbonylamino)-propyI]-l.H r -indol-5-yl ester
- the solution stability of the example compounds were assessed using an accelerated stress test.
- the compound was dissolved in pH 5, 0.025 M sodium citrate buffer (5-15 ⁇ g/mL).
- 2 mL of each solution in a glass vial was heated at 75°C for 14 days.
- Samples were analyzed periodically using HPLC and % degradation was calculated for the sample.
- the predicted shelf life 25°C was based on the loss of 10% compound (T 0 ) and the fact that the rate of degradation for a first order reaction decreased 50% for every 10°C drop in temperature.
- Example 2 The predicted shelf lives for representative compounds of Formula I are listed in Table 2.
- the parent compound, ⁇ -methylserotonin, and the corresponding propionic acid ester derivative (Example 1) are included for reference.
- Example 1 a straight chain alkyl ester, did not provide an increase in the stability of the parent compound.
- the other Examples in Table 1 more sterically hindered esters, were less susceptible than the parent compound to both oxidative degradation and ester hydrolysis as illustrated by the decreased level of degradation observed under the experimental stress conditions.
Abstract
Novel 3-(2-aminopropyl)-H-indol-5-ols useful for lowering and controlling IOP and treating glaucoma are disclosed.
Description
5-HYDROXY INDOLE DERIVATIVES FOR TREATING GLAUCOMA
The present invention is directed to novel substituted 3-(2-aminopropyl)-lH- indol-5-ols. These novel compounds are useful for lowering and controlling normal or elevated intraocular pressure (IOP) and treating glaucoma.
Background of the Invention
The disease state referred to as glaucoma is characterized by a permanent loss of visual function due to irreversible damage to the optic nerve. The several morphologically or functionally distinct types of glaucoma are typically characterized by elevated IOP, which is considered to be causally related to the pathological course of the disease. Ocular hypertension is a condition wherein intraocular pressure is elevated but no apparent loss of visual function has occurred; such patients are considered to be a high risk for the eventual development of the visual loss associated with glaucoma. If glaucoma or ocular hypertension is detected early and treated promptly with medications that effectively reduce elevated intraocular pressure, loss of visual function or its progressive deterioration can generally be ameliorated. Drug therapies that have proven to be effective for the reduction of intraocular pressure include both agents that decrease aqueous humor production and agents that increase the outflow facility. Such therapies are in general administered by one of two possible routes, topically (direct application to the eye) or orally.
There are some individuals who do not respond well when treated with certain existing glaucoma therapies. There is, therefore, a need for other topical therapeutic agents that control IOP.
It has been found that serotonergic compounds which possess agonist activity at 5-ΗT2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma, see commonly owned co-pending application,
PCT US99/19888. Compounds that act as agonists at 5-HT2 receptors are known and have shown a variety of utilities, primarily for disorders or conditions associated with the central nervous system (CNS). U.S. Patent 5,494,928 discloses certain 2-(indol-l- yl)-ethylamine derivatives that are 5-HT2c agonists for the treatment of obsessive compulsive disorder and other CNS derived personality disorders. U.S. Patent
5,571,833 discloses tryptamine derivatives that are 5-HT2 agonists for the treatment of portal hypertension and migraine. U.S. Patent 5,874,477 discloses a method for treating malaria using 5-HT2A/2C agonists. U.S. Patent 5,902,815 discloses the use of
5-HT2A agonists to prevent adverse effects of NMDA receptor hypo-function. WO98/31354A2 discloses 5-HT B agonists for the treatment of depression and other CNS conditions. O00/12475 discloses indoline derivatives as 5-HT2B and 5-HT2C receptor agonists for the treatment of a variety of disorders of the central nervous system, but especially for the treatment of obesity. WO00/35922 discloses certain pyrazino[l ,2-α]quinoxaline derivates as 5-HT2c agonists for the treatment of obsessive-compulsive disorder, depression, eating disorders, and other disorders involving the CNS. Agonist response at the 5-HT A receptor is reported to be the primary activity responsible for hallucinogenic activity, with some lesser involvement of the 5-HT2 receptor possible [Psychopharmacology, Vol. 121 :357, 1995].
A specific disclosure in co-pending application PCT/US99/19888 relates to certain substituted α-methyltryptamines which are effective agents for lowering intraocular pressure in mammals (Table 1). However, when a phenolic moiety is included in this substitution, e.g. a hydroxyl group at indole ring position five such compounds can be particularly sensitive to oxidation reactions well known to occur with phenolic compounds in general, including hydroxytryptamines [J. Phys. Chem. 103, 8606 (1999), Chem. Res. Toxicol. 1 1, 639 (1998), J. Org. Chem. 52, 2817 (1987), J. Pharm. Sci. 77, 911 (1988)], which are of particular relevance to the present application. Protection of such hydroxy substituted tryptamines from oxidation can be accomplished by derivatization of the aryl hydroxy group to provide a suitable ester, carbamate, or carbonate. Though the ester, carbamate, or carbonate derivatives do not themselves possess a high affinity for the above mentioned receptors, they do have utility in the treatment of glaucoma since suitably protected phenols can be cleaved in vivo either by chemical hydrolysis or through the action of tissue esterases, thereby delivering the desired therapeutic agent, that is, the desired hydroxytryptamine compound in the present case. The concept of utilizing such derivatized phenolic compounds as chemical delivery agents is well known in the art [Drugs Pharm. Sci. 53, 221 (1992), Pharm. Res., 168 (1984)].
The present invention is directed to new derivatives of 3-(2-aminopropyl)-lH- indol-5-ol which can be used to lower and control IOP associated with normal-tension glaucoma, ocular hypertension, and glaucoma in warm blooded animals, including man. The compounds are formulated in pharmaceutical compositions suitable for topical delivery to the eye.
Description of the Preferred Embodiments
Compounds that are useful according to the present invention are represented by the following Formula I.
FORMULA I
Wherein G is chosen from hydrogen, halogen, or C^aHcyl;
R is chosen from C3.6alkyl, C3.6alkyl substituted with hydroxyl, CO(OC]- alkyl),
CON(C alkyl)2, or C2.4alkenyl substituted by phenyl;
R1 is chosen from hydrogen, C^aHcyl; and pharmaceutically acceptable salts and solvates of the compounds.
It is recognized that compounds of Formula I can contain one or more chiral centers. This invention contemplates all enantiomers, diastereomers and. mixtures thereof.
In the above definitions, the total number of carbon atoms in a substituent group is indicated by the Ci-j prefix where the numbers i and j define the number of carbon atoms; this definition includes branched chain, and cyclic alkyl or (cyclic alkyl)alkyl groups.
It is important to recognize that a substituent may be present either singly or multiply when incorporated into the indicated structural unit. For example, the substituent halogen, which means fluorine, chlorine, bromine, or iodine, would indicate that the unit to which it is attached may be substituted with one or more halogen atoms, which may be the same or different.
SYNTHESIS
The compounds of Formula I can be readily prepared from, for example, α- methyl-5-hydroxy-tryptarnine [J. Med. Chem. 33, 755 (1990), J. Org. Chem. 25, 1548 (I960)] or a desirably substituted derivative of structure 1 wherein G is as defined previously. That is, compounds of Formula I can be prepared by reacting the appropriate indole 1, or preferably a suitable amino-protected intermediate, e.g. 2 (Scheme 1 ) with the desired activated acid derivative, such as an acid halide or active ester, or the like, to provide the esters 3. Removal of the N-protective group from the intermediate 3 provides the desired compounds of Formula I.
Scheme 1
The indole derivatives of interest for use as starting materials for the preparation of 1 can be either purchased from commercial suppliers or prepared by well known methods [Comp. Heterocycl. Chem. II, Vol. 2: 1 19, 1996; Indoles, Sundberg, 1996]. For example, one such approach begins with the desired 5-alkoxy- 2-nitrotoluene 5 and proceeds via a Leimgruber-Batcho indole synthesis [J. Med.Chem. 22, 63 (1979) and U.S. Patent 3,732,245] to give the desired indoles 7 (Scheme 2). Intermediates 7 can be readily transformed into indoles 1 by well known methods [J. Med. Chem. 33, 755 (1990), J. Org. Chem. 25, 1548 (I960)].
Scheme 2
The compounds of this invention, Formula I, can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g.. topically, intracamerally, or via an implant). The compounds are preferably incorporated into topical ophthalmic formulations for delivery to the eye. The compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving a compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. Furthermore, the ophthalmic solution may contain an agent to increase viscosity, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. Gelling agents can also be used, including, but not limited to, gellan and xanthan gum. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-974. or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
The compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 5 to 8. The compounds will normally be contained in these formulations in an amount 0.01% to 5% by weight, but preferably in an amount of 0.25% to 2% by weight. Thus, for topical presentation 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.
The compounds can also be used in combination with other agents for treating glaucoma, such as, but not limited to, β-blockers (e.g., timolol. betaxolol,
levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), αl antagonists (e.g. nipradolol), ct2 agonists (e.g., iopidine and brimonidine), miotics (e.g., pilocarpine and epinephrine), prostaglandin analogs (e.g., latanoprost, travaprost, unoprostone, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368; and 5,151,444, "hypotensive lipids" (e.g., lumigan and compounds set forth in 5,352,708), and neuroprotectants (e.g., compounds from U.S. Patent No. 4,690,931, particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N. 06/203350, and appropriate compounds from WO94/13275, including memantine.
The following examples are given to illustrate the preparation of compounds that are the subject of this invention but should not be construed as implying any limitations to the claims. The preferred compounds of Formula I are described in Examples 2-4. Especially preferred compounds are those set forth in Examples 3 and 4. The most preferred is the compound of Example 3. The proton magnetic resonance spectrum of each compound of the Examples was consistent with the assigned structure. All compounds had satisfactory HPLC analysis.
EXAMPLE 1 Propionic acid 3-(2-aminopropyI)-l-fiT-indol-5-yl ester
Step A. [2-(5-Hydroxy-lJ7-indol-3-yI)-l-methylethyl]carbamic acid 9//-fluoren-9- ylmethyl ester
A 35 mL round bottom flask was charged with 3-(2-aminopropyl)-lH-indol-5- ol (0.20 g, 0.65 mmol) was added NaΗCO3 (0.9 g, 11 mmol), water (2 mL) and 1,4- dioxane (8 mL). 9-Fluorenylmethyl chloroformate (0.20 g, 0.82 mmol) was added and the mixture stirred for 16 h at 23 °C. TLC analysis indicated that the reaction was complete and the solution decanted into aqueous NaHCO3, then extracted with ether
(2 x 30 mL). The combined organic extracts were washed with water (20 mL), dried over MgSO and concentrated. The crude product was purified by chromatography
(silica, 65:35 hexanes:ethyl acetate) to furnish the title compound (0.26 g, 97 %):
'H NMR (CDC13) δ 7.88 (bs, 1H), 7.76 (d, J = 6 Hz, 2H), 7.57 (d, J = 6 Hz, 2H),
7.44-7.19 (m, 6H), 7.07 (s, 1H), 6.94 (s, 1H), 6.77 (dd, J = 8, 2 Hz, 1H), 4.8 (m, 1H),
4.45 (m, J = 8 Hz, 2H), 4.20 (m, J = 8 Hz, 1H), 2.81 (bm, 2H), 1.15 (d, J = 8 Hz, 3H); MS(ESI) m/z 430 (M + NH4)+, 413 (M + H)+.
Step B. Propionic acid 3-[2-(9 -fluoren-9-ylmethoxycarbonylamino)propyl]-lH- indol-5-yl ester
A 25 mL round bottom flask fitted with magnetic stirring bar and septum inlet was charged with the product from Step A (0.24 g, 0.58 mmol), CH2C12 (10 mL). and diisopropylethyl amine (0.12 g, 0.9 mmol). Propionyl chloride (0.083 g, 0.9 mmol) was added followed by addition of DMAP (0.005g, 0.04 mmol). The solution was stirred for 14 h at 23°C, then poured into dilute aqueous NaHCO3 and extracted with ether (2 x 20 mL). The combined extracts were dried (MgSO4), filtered, and concentrated. The crude material was purified by chromatography (silica. 7:3 hexanes:ethyl acetate) to furnish the title compound (0.15 g, 55%): 1H NMR (CDC13) δ 8.03 (bs, 1H), 7.76 (d, J = 6 Hz, 2H), 7.56 (d, J = 6 Hz, 2H), 7.43-7.29 (m, 7H), 6.99 (bs, 1H), 6.77 (dd, J = 8, 2 Hz, 1H), 4.43 (m, 1H), 4.37 (m, J = 8 Hz, 2H), 4.20 (m. J = 8 Hz, 1H), 2.84 (bm, 2H), 2.58 (q, J = 6 Hz, 2H), 1.25 (q, J = 6 Hz, 3H), 1.15 (d, J = 8 Hz, 3H); MS(ESI) m/z 486 (M + NH4)+, 469 (M + H)+.
Step C: Propionic acid 3-(2-aminopropyl)-lH-indol-5-yl ester
A 10 mL round bottom flask fitted with magnetic stirring bar and septum inlet was charged with the product from Step B (0.14 g, 0.30 mmol), DMF (4 mL), and piperidine (1 mL, 0.9 mmol). The solution was stirred for 5 minutes, then poured into dilute aq. NaHCO3 (1 mL) and extracted with ethyl acetate (3 x 10 mL), and CH2C12
(1 x 10 mL). The combined organic extracts were concentrated and the crude material purified by chromatography (silica, gradient, 10% to 50% MeOH in CH2C12) to provide the title compound (0.046 g, 63%): Η NMR (CDC13) δ 8.1 (bs, 1H), 7.31 (dd, J = 8. 2 Hz, 1H), 7.2 (s, 1H), 6.92 (d, J = 2 Hz, 1H), 6.85 (dd, J = 8, 2 Hz, 1H), 3.2 (m, 1H), 2.9 - 2.4 (m, 4H), 1.29 (t, J = 8 Hz, 3H), 1.17 (d, J = 8 Hz. 3H); MS(ESI) m/z 247
(M + H)+.
EXAMPLE 2
Isobutyric acid 3-(2-aminopropyl)-lH-indol-5-yl ester
Step A. Isobutyric acid 3-[2-(9-flr-fluoren-9-ylmethoxycarbonylamino)-propyl]- li/-indol-5-yl ester
Prepared as described in Example 1, Step B but using isobutyryl chloride: oil,
83% yield; 1H NMR (CDC13) δ 8.05 (bs, 1H), 7.75 (d, J = 6 Hz, 2H), 7.54 (d, J = 6 Hz. 2H), 7.43-7.29 (m, 7H), 6.97 (bs, 1H), 6.87 (dd, J = 8, 2 Hz, 1H), 4.43 (m. 1H),
4.37 (m. J = 8 Hz, 2H), 4.20 (m, J = 8 Hz, 1H), 2.87 (bm, 2H), 2.73 (hept, J = 6 Hz,
1 H), 1.25 (d, J = 6 Hz, 6H), 1.15 (d, J = 8 Hz, 3H); MS(ESI) m/z 500 (M + NH4)\ 483
(M + H)\
Step B. Isobutyric acid 3-(2-aminopropyl)-l jT-indol-5-yl ester
Prepared from the product of Step A as described in Example 1, Step C: oil, 58% yield; 1H NMR (CDC13) δ 8.2 (bs, IH), 7.3 (d, J = 8 Hz, IH), 7.2 (s. IH), 7.0 (s, IH), 6.85 (dd, J = 8, 2 Hz, IH), 3.2 (m, IH), 2.9 - 2.4 (m, 2H), 1.6 (m, IH), 1.31 (d, J = 6 Hz, 6H), 1.17 (d, J = 8 Hz, 3H); MS(ESI) m/z 261 (M + H)+.
EXAMPLE 3 2,2-Dimethyl-propionic acid 3-(2-aminopropyI)-li/-indol-5-yl ester
Step A. 2,2-Dimethyl-propionic acid 3-[2-(9 /-fluoren-9- ylmethoxycarbonylamino)-propyl]-l//-indol-5-yl ester
Prepared as described in Example 1, Step B but using pivaloyl chloride: oil, 49% yield; 1H NMR (CDC13) δ 8.05 (bs, IH), 7.75 (d, J = 6 Hz, 2H), 7.54 (d, J = 6
Hz, 2H), 7.43-7.29 (m, 7H), 6.97 (bs, IH), 6.87 (dd, J = 8, 2 Hz, IH), 4.43 (m, IH).
4.37 (m, J = 8 Hz, 2H), 4.20 (m, J = 8 Hz, IH), 2.87 (bm, 2H), 1.6 (s, 9H), 1.15 (d, J =
8 Hz, 3H); MS(ESI) m/z 514 (M + NH^, 497 (M + H)+.
Step B. 2,2-Dimethyl-propionic acid 3-(2-aminopropyl)-l-ff-indol-5-yl ester
Prepared from the product of Step A as described in Example 1 , Step C: oil,
45% yield; Η NMR (CDC13) δ 8.1 (bs, IH), 7.3 (d, J = 8 Hz, IH), 7.2 (s, I H), 7.0 (d,
J = 2.2 Hz, IH), 6.85 (dd, J = 8, 2 Hz, IH), 3.2 (m, IH), 2.8 (dd, J - 14.2, 4.8 Hz, IH),
2.62 (dd, J = 14.2, 6.0 Hz, IH), 1.39 (s, 9H), 1.17 (d, J = 8 Hz, 3H); MS(ESI) m/z 275 (M + H)+.
EXAMPLE 4 Cyclopropanecarboxylic acid 3-(2-aminopropyl)-l//-indol-5-yl ester
Step A. Cyclopropanecarboxylic acid 3-[2-(9 jT-fluoren-9- ylmethoxycarbonylamino)-propyI]-l.Hr-indol-5-yl ester
Prepared as described in Example 1, Step B but using cyclopropanecarbonyl chloride: oil, 57% yield; 1H NMR (CDC13) δ 8.05 (bs, IH), 7.76 (d, J = 6 Hz, 2H), 7.54 (d, J = 6 Hz. 2H), 7.43-7.29 (m, 7H), 6.97 (bs, IH), 6.87 (dd, J = 8, 2 Hz, IH),
4.7 (m, IH), 4.4 (m, J = 8 Hz, 2H), 4.20 (m. J = 8 Hz, IH), 4.0 (bs, IH). 2.87 (bm,
2H), 1.8 (m, IH), 1.7-1.1 (bm, 7H); MS(ESI) m/z 498 (M + NH4)+, 481 (M + H)+.
Step B. Cyclopropanecarboxylic acid 3-(2-aminopropyl)-lH-indol-5-yl ester
Prepared from the product of Step A as described in Example 1, Step C: oil, 62% yield; 1H NMR (CDC13) δ 8.1 (bs, IH), 7.3 (d, J = 8 Hz, IH), 7.2 (s, IH), 7.0 (s, IH), 6.85 (dd, J = 8, 2 Hz, IH), 3.2 (m, IH), 2.8 (dd, J = 14.2, 4.8 Hz, IH), 2.62 (dd, J = 14.2, 6.0 Hz, IH), 1.9 (m, IH), 1.2 (m, 4H), 1.17 (d, J = 8 Hz, 3H); MS(ESI) m/z 259 (M + H)+.
EXAMPLE 5
EXAMPLE 6
EXAMPLE 8
EXAMPLE 9
Solution Stability Studies
The solution stability of the example compounds were assessed using an accelerated stress test. The compound was dissolved in pH 5, 0.025 M sodium citrate buffer (5-15 μg/mL). In duplicate, 2 mL of each solution in a glass vial was heated at 75°C for 14 days. Samples were analyzed periodically using HPLC and % degradation was calculated for the sample. The predicted shelf life (25°C) was based on the loss of 10% compound (T 0) and the fact that the rate of degradation for a first order reaction decreased 50% for every 10°C drop in temperature.
The predicted shelf lives for representative compounds of Formula I are listed in Table 2. The parent compound, α-methylserotonin, and the corresponding propionic acid ester derivative (Example 1) are included for reference. Example 1, a straight chain alkyl ester, did not provide an increase in the stability of the parent compound. The other Examples in Table 1 , more sterically hindered esters, were less susceptible than the parent compound to both oxidative degradation and ester hydrolysis as illustrated by the decreased level of degradation observed under the experimental stress conditions.
Claims
1. A compound of the formula:
wherein G is chosen from hydrogen, halogen, or Cι.4alkyl;
R is chosen from C3-6alkyl, C3.6alkyl substituted with hydroxyl, CO(OC)-4alkyl),
CON(Cι- alkyl)2, or C^alkenyl substituted by phenyl;
2. The compound of Claim 1 selected from the group consisting of: isobutyric acid 3-(2-aminopropyl)-lH-indol-5-yl ester; 2,2-dimethyl-propionic acid 3-(2-aminopropyl)-lH-indol-5-yl ester; and cyclopropanecarboxylic acid 3-(2-aminopropyl)-lH-indol-5-yl ester.
3. The compound of Claim 2 that is 2,2-dimethyl-propionic acid 3-(2- aminopropyl)-lH-indol-5-yl ester.
4. A topical ophthalmic composition for lowering and controlling normal or elevated IOP, comprising a pharmaceutically effective amount of a compound of
Claim 1.
5. A method for lowering and controlling normal or elevated IOP, which comprises administering a pharmaceutically effective amount of a compound of Claim 1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001216035A AU2001216035A1 (en) | 2000-03-17 | 2000-11-14 | 5-hydroxy indole derivatives for treating glaucoma |
US10/220,997 US6806285B1 (en) | 2000-03-17 | 2000-11-14 | 5-Hydroxyl indole derivatives for treating glaucoma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19020500P | 2000-03-17 | 2000-03-17 | |
US60/190,205 | 2000-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001070686A1 true WO2001070686A1 (en) | 2001-09-27 |
Family
ID=22700419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/031144 WO2001070686A1 (en) | 2000-03-17 | 2000-11-14 | 5-hydroxy indole derivatives for treating glaucoma |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001216035A1 (en) |
WO (1) | WO2001070686A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1515974A2 (en) * | 2002-06-17 | 2005-03-23 | Merck & Co., Inc. | Novel maxi-k channel blockers, methods of use and process for making the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000333A1 (en) * | 1991-06-21 | 1993-01-07 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
WO1994003162A1 (en) * | 1992-07-31 | 1994-02-17 | Glaxo Group Limited | Medicaments for the treatment or prevention of elevated intraocular pressure |
WO1998031354A2 (en) * | 1997-01-17 | 1998-07-23 | Smithkline Beecham Plc | Use of 5-ht2b agonists or potentiators in cns disorders |
WO2000016761A2 (en) * | 1998-09-18 | 2000-03-30 | Alcon Laboratories, Inc. | Serotonergic 5ht2 agonists for treating glaucoma |
-
2000
- 2000-11-14 WO PCT/US2000/031144 patent/WO2001070686A1/en active Application Filing
- 2000-11-14 AU AU2001216035A patent/AU2001216035A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000333A1 (en) * | 1991-06-21 | 1993-01-07 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
WO1994003162A1 (en) * | 1992-07-31 | 1994-02-17 | Glaxo Group Limited | Medicaments for the treatment or prevention of elevated intraocular pressure |
WO1998031354A2 (en) * | 1997-01-17 | 1998-07-23 | Smithkline Beecham Plc | Use of 5-ht2b agonists or potentiators in cns disorders |
WO2000016761A2 (en) * | 1998-09-18 | 2000-03-30 | Alcon Laboratories, Inc. | Serotonergic 5ht2 agonists for treating glaucoma |
Non-Patent Citations (6)
Title |
---|
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LYON, ROBERT A. ET AL: "Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens", XP002161467, retrieved from STN Database accession no. 109:47843 * |
EUR. J. PHARMACOL. (1988), 145(3), 291-7 * |
GUPTA Y K ET AL: "THERAPEUTIC POTENTIALS OF 5-HT RECEPTOR MODULATORS", INDIAN JOURNAL OF PHARMACOLOGY,XX,XX, vol. 26, no. 2, 1 June 1994 (1994-06-01), pages 94 - 107, XP000571272, ISSN: 0253-7613 * |
ISMAIEL, ABD M. ET AL: "5-HT1 and 5-HT2 binding profiles of the serotonergic agents.alpha.-methylserotonin and 2-methylserotonin", J. MED. CHEM. (1990), 33(2), 755-8, XP000876594 * |
OSBORNE N N ET AL: "DO BETA-ADRENOCEPTORS AND SEROTONIN 5-HT1A RECEPTORS HAVE SIMILAR FUNCTIONS IN THE CONTROL OF INTRAOCULAR PRESSURE IN THE RABBIT?", OPHTHALMOLOGICA,CH,KARGER, BASEL, vol. 210, 1996, pages 308 - 314, XP002051581, ISSN: 0030-3755 * |
OSBORNE N N: "SEROTONIN AND MELATONIN IN THE IRIS/CILIARY PROCESSES AND THEIR INVOLVEMENT IN INTRAOCULAR PRESSURE", ACTA NEUROBIOLOGIAE EXPERIMENTALIS,PL,WARSZAW, vol. 54, no. SUPPL, 1994, pages 57 - 64, XP000878634, ISSN: 0065-1400 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1515974A2 (en) * | 2002-06-17 | 2005-03-23 | Merck & Co., Inc. | Novel maxi-k channel blockers, methods of use and process for making the same |
EP1515974A4 (en) * | 2002-06-17 | 2007-02-28 | Merck & Co Inc | Novel maxi-k channel blockers, methods of use and process for making the same |
US7294646B2 (en) | 2002-06-17 | 2007-11-13 | Merck & Co. Inc. | Maxi-k channel blockers, methods of use and process for making the same |
Also Published As
Publication number | Publication date |
---|---|
AU2001216035A1 (en) | 2001-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6956036B1 (en) | 6-hydroxy-indazole derivatives for treating glaucoma | |
US6660870B1 (en) | 2-acylaminobenzimidazole derivatives for treating glaucoma | |
US6806285B1 (en) | 5-Hydroxyl indole derivatives for treating glaucoma | |
CA2402403A1 (en) | 6-hydroxy-indazole derivatives for treating glaucoma | |
AU2001219180B2 (en) | 5-hydroxy indazole derivatives for treating glaucoma | |
US6960608B2 (en) | Fused indazoles and indoles and their use for the treatment of glaucoma | |
WO2001040183A1 (en) | 1-aminoalkyl-1h-indoles for treating glaucoma | |
AU2002259312B2 (en) | Novel arylaminopropane analogues and their use for the treatment of glaucoma | |
AU2001219180A1 (en) | 5-hydroxy indazole derivatives for treating glaucoma | |
AU2002259312A1 (en) | Novel arylaminopropane analogues and their use for the treatment of glaucoma | |
EP1268482B1 (en) | Pyranoindoles for treating glaucoma | |
US20070293475A1 (en) | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma | |
AU2001216034A1 (en) | Pyranoindoles for treating glaucoma | |
AU2003300915A1 (en) | Novel benzopyran analogs and their use for the treatment of glaucoma | |
US20060052431A1 (en) | 5-Hydroxy indazole derivatives for treating glaucoma | |
WO2001070686A1 (en) | 5-hydroxy indole derivatives for treating glaucoma | |
US7012090B1 (en) | Pyranoindoles for treating glaucoma | |
US7439262B1 (en) | Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP KR MX PL US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10220997 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |